Post by Peter van Rossum

💡Is it time to start factoring immunosuppression into how we design radiotherapy for stage III NSCLC? 👉🏻https://lnkd.in/evzZw9Yx In our new paper: • We developed a pretreatment prediction model for severe radiation-induced lymphopenia in unresectable stage III NSCLC • Developed in the US and externally validated in 3 European centers • Durvalumab benefit was observed in patients with a low predicted risk of severe lymphopenia, but NOT in those with a high predicted risk❗️ This suggests the model can identify patients in whom treatment-related immune suppression is so substantial that we need to change radiotherapy or else durvalumab may be useless. Many thanks to shared first co-author Pim Damen, and all others Francesco Cortiula Brian Hobbs Lorenzo De Marchi Radhe Mohan Max Peters Famke Schneiders Dirk De Ruysscher Robin Wijsman Joost Verhoeff Ting Xu Zhongxing Liao Steven Hsesheng Lin. #NSCLC #Immunotherapy #Radiotherapy #Durvalumab #Lymphopenia IJROBP The Red Journal Amsterdam UMC - Radiotherapie UT MD Anderson Lung Cancer PRG Amsterdam UMC Amsterdam UMC - Cancer Center Amsterdam European Society for Radiotherapy and Oncology (ESTRO) American Society for Radiation Oncology (ASTRO) Immunorad